OPEN-LABEL DOSE-ESCALATION DATA FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF PULSED, INHALED NITRIC OXIDE (INO) IN SUBJECTS AT RISK OF PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY FIBROSIS (PH-PF) ON LONG TERM OXYGEN THERAPY

(PH-PF) ON LONG TERM OXYGEN THERAPY B PURPOSE: b Pulmonary fibrosis (PF) is made up of a variety of fibrotic lung diseases, the largest of which is IPF (Idiopathic Pulmonary Fibrosis). Inhaled Nitric Oxide (iNO) at a dose of 30 mcg/kg IBW/hr (Cohort 1) has been demonstrated to improve moderate to vigorous physical activity (MVPA) by 34% (placebo-corrected) in an 8-week controlled trial. [Extracted from the article]